AXSM – axsome therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

AXSM

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

1/28

01:53 pm

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/21

09:43 am

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/21

09:43 am

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/21

07:17 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

1/21

07:17 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

1/14

08:42 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Report

1/13

09:59 am

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/13

09:59 am

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/13

08:03 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.

Report

1/8

08:02 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.

Report

1/8

08:02 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.

Report

1/8

08:02 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.

Report

1/8

08:02 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.

Report

1/8

07:20 am

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/8

07:20 am

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/8

06:17 am

axsm

Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Low Report

Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Report

1/8

06:17 am

axsm

Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Low Report

Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Report

1/6

12:25 pm

axsm

Rating for AXSM

Low Report

Rating for AXSM

Report

1/6

09:02 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.

Report

1/5

08:42 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.

Medium Report

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.

Report

1/5

07:03 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Medium Report

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Report

1/2

10:11 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.

Report

1/2

10:11 am

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.

Report

12/31

03:07 pm

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..

Report

12/31

02:14 pm

axsm

Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Low Report

Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.